Top 10 HK Stock Losers (9.1)
Top Gainers&Losers·Analyst Initiates Buy on GenFleet, Citing GFH276-Driven Valuation and Emerging Global RAS Franchise
Tip Ranks·- Goldman Sachs analyst Dr. Linhai Percy Zhao initiated coverage on GenFleet Therapeutics H Shares with a Buy rating. - The rating is driven by GenFleet's strong market positioning in RAS-targeted therapies and GFH276 serving as the core value driver with significant sales potential. - Upcoming clinical catalysts and an experienced R&D organization support its long-term growth prospects, despite potential execution and competition risks.